cagrilintide semaglutide cagrisema phase 3 results 2024 2025 combination RESEARCH ARTICLE: Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 @SubodhVermaMD https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.125.26055 cagrisema cagrilintide semaglutide phase 3

(2024) showed that GHRP-6 prevented doxorubicin-induced myocardial and extra-myocardial damage in rats by attenuating pro-oxidant activity, enhancing antioxidant reserves, protecting mitochondrial ultrastructure, and upregulating the anti-apoptotic gene Bcl-2

Some people even experience better results with the combination than with either medication alone

Compared with SGLT2is, GLP-1s were associated with a slightly higher uveitis risk (RR, 1.17

However, as animal models and isolated tissue experiments were mainly used, the authors cautioned that further research is needed to establish whether the same mechanism occurs in humans